Search Results
Your search for 27 matches 3291 pages
Showing 2101 - 2150Adding Idelalisib to Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
As reported by Zelenetz et al in The Lancet Oncology, an interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase δ inhibitor idelalisib (Zydelig) to bendamustine/rituximab (Rituxan) in patients with relapsed or refractory chronic lymphocytic...
2017 Oncology Meetings
FEBRUARY ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 23-25 • Orlando, Florida For more information: http://immunosym.org FACTOR (Funding, Awareness, Collaboration, Trials, Osteosarcoma Research) Miami Conference 2017February 24-25 • Coral Gables, Florida For more information:...
ASCEND-4 Study Shows 45% Reduction in Risk of Disease Progression for NSCLC Patients on First-Line Ceritinib
Compared to chemotherapy, the use of first-line ceritinib (Zykadia) resulted in a statistically significant and clinically meaningful improvement in median progression-free survival, with an estimated 45% reduction in disease progression risk, as well as significant improvements in quality of...
ECCO 2017: Pembrolizumab Shows Activity in Mucosal Melanoma in Multiple KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO) (Abstract 1142). Until now, mucosal melanoma has often...
Benefits of Multiparametric Magnetic Resonance Imaging in Clinically Significant Prostate Cancer
In the UK PROMIS study reported in The Lancet, Ahmed et al found that use of multiparametric magnetic resonance imaging (MP-MRI) might reduce the need for transrectal ultrasound (TRUS)-guided prostate biopsy and may improve detection of clinically significant prostate cancer. Study Details In the ...
Potential Surrogate for All-Cause Mortality Risk in Localized Unfavorable-Risk Prostate Cancer
In a study reported in JAMA Oncology, Royce et al found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and androgen-deprivation therapy in men with localized unfavorable-risk prostate cancer. Study Details...
Regorafenib in Advanced Nonadipocytic Soft-Tissue Sarcoma
Mir et al found that regorafenib (Stivarga) was active in patients with advanced nonadipocytic soft-tissue sarcoma previously treated with an anthracycline, according to a French-Austrian phase II trial reported in The Lancet Oncology. Regorafenib, a kinase inhibitor, should be evaluated further in ...
2017 Oncology Meetings
FEBRUARY Immuno-Oncology 360°February 1-3 • New York, New YorkFor more information:http://theconferenceforum.org/conferences/immuno-oncology-360/overview/ 14th APOS Annual ConferenceFebruary 15-18 • Orlando, Florida For more information: apos-society.org/annual-conference/ Genitourinary Cancers...
What Have We Got to Lose?
Tuesday morning was the regular time for the departmental meeting—an opportunity to discuss cases, troubleshoot, debrief, and expedite the necessary allied health referrals. As usual, patient cases were being discussed in alphabetical order of the attending oncologist. We were already three...
Rucaparib in Previously Treated BRCA Mutation–Associated Ovarian Cancer
On December 19, 2016, rucaparib (Rubraca) was granted accelerated approval for the treatment of patients with deleterious BRCA mutation–associated (germline or somatic) advanced ovarian cancer who have received two or more prior chemotherapy regimens.1,2 The U.S. Food and Drug Administration (FDA) ...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Technically, vitamin D is a secosteroid hormone, not a vitamin. Increasing evidence indicates that vitamin D exerts effects beyond calcium homeostasis. Importantly, for example, higher serum vitamin D levels are associated with better cancer outcomes, including survival.1-3 The protective effects...
Survivorship Symposium 2017: Almost Half of Partners and Caregivers of Young Breast Cancer Survivors Experience Long-Lasting Anxiety
While evidence is mounting on the physical and emotional challenges many cancer caregivers experience, few studies have addressed the experience of partners of young adults with cancer. Now, a new study evaluating the psychosocial concerns and mental health in the partners of young survivors of...
Highlights From the 2017 Gastrointestinal Cancers Symposium and Cancer Survivorship Symposium
The 2017 Gastrointestinal Cancers Symposium was held from January 19–21. Direct your patients to www.cancer.net/blog to read about the recent findings in esophageal and colorectal cancers. In addition, the Cancer Survivorship Symposium is being held from January 27–28. Visit the Cancer.Net blog to ...
Survivorship Symposium 2017: Physical and Psychological Factors Contribute to Decreased Physical Activity in 75% of Patients With Cancer
Although, in the past, patients with cancer were often counseled by their physicians to rest and reduce their physical activity, according to the American Cancer Society, emerging data are showing that exercise is not only safe and possible during cancer treatment, it can improve patients’...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations that I face as a clinician is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center, Ann Arbor, told the more than 250...
Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer
In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herceptin) and an aromatase inhibitor in the first-line setting significantly improved progression-free ...
Lu-177 Dotatate Improves Progression-Free Survival in Midgut Neuroendocrine Tumors
In a phase III trial (NETTER-1) reported in The New England Journal of Medicine, Strosberg et al found that the addition of the targeted radiotherapeutic agent lutetium Lu-177 dotatate to octreotide long-acting repeatable (LAR) (Sandostatin LAR) significantly improved progression-free...
Tucatinib Shows Clinical Benefit in Phase I Trial in HER2-Positive Breast Cancer
Phase I clinical trial data published by Moulder-Thompson et al in Clinical Cancer Research reported that the investigational anticancer agent tucatinib (formerly ONT-380) showed 'notable activity' in the treatment of HER2-positive breast cancer with . The 50 women treated had disease...
Pembrolizumab Studied in Locally Advanced or Metastatic Urothelial Cancer
As reported by Plimack et al in The Lancet Oncology, pembrolizumab (Keytruda) has shown activity in patients in the locally advanced or metastatic urothelial carcinoma cohort included in the phase Ib KEYNOTE-012 trial. Study Details In the study, 33 patients with locally advanced or metastatic...
Colonoscopy Screening in Older Adults
A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found...
Study Suggests No Evidence for Screening Mammography Cutoff Age
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear cutoff age to stop breast cancer screening. Screening mammography among women aged 75 years was associated with higher cancer detection and lower recall rates than among younger women in the study. These...
BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer
Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html 2017 Highlights of ASH in North...
Benefit of Extended Adjuvant Endocrine Therapy Not Upheld in Multiple Studies Reported in San Antonio
Extended endocrine therapy with an aromatase inhibitor did not improve disease-free survival in patients with hormone receptor–positive breast cancer enrolled in three studies presented at the 2016 San Antonio Breast Cancer Symposium. The results stand in contrast to the phase III National Cancer...
Atezolizumab Shows Activity in First-Line Treatment of Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Balar et al found that first-line atezolizumab (Tecentriq) produced durable responses in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. In the study, 119 patients from 47 sites in North America and Europe who were ...
Investigational Immunotherapy for Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
Valerian
Scientific Names: Valeriana officinalis, Valeriana radix Common Names: Garden valerian, Indian valerian, Pacific valerian, garden heliotrope Overview A perennial flowering plant prevalent in Europe, Asia, and North America, valerian has a long medicinal history as a relaxant. Its potential as a...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html Advances in Medical and Surgical Management...
Profound Answers to Simple Questions
A few years ago, I had the good fortune to join a research team that intended to create a device to help dying children express their wants and needs despite communication challenges. The brain tumor team at SickKids [also known as The Hospital for Sick Children] had cared for several children...
Advocacy Group to Fund $1.6 Million in Grants for 8 Early Detection Ovarian Cancer Research Projects
Tina’s Wish, a nonprofit organization dedicated exclusively to funding scientific research for the early detection of ovarian cancer, recently announced its eight 2017–2018 individual grant recipients after soliciting proposals nationally for the first time. Researchers from Dana-Farber Cancer...
Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
On March 10, 2015, the U.S. Food and Drug Administration (FDA) granted regular approval to dinutuximab (formerly known as chimeric 14.18 antibody; Unituxin) for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid...
NCCN Launches Campaign to Eradicate Fatal Vincristine Errors
It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network®...
Noteworthy Antitumor Activity Seen in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes encode receptor tyrosine kinases, and when they are mutated, cell signaling malfunctions, leading to...
FDA Approves Daratumumab in Combination Therapy for Patients With Multiple Myeloma Receiving at Least One Prior Treatment
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior...
‘Clinically Useful’ Findings for Brentuximab Vedotin in CTCL, Rituximab Maintenance in MCL
Positive studies about brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting of the American Society for Hematology (ASH). “These abstracts each focus on approved agents and...
ASH 2016: Interim Analysis Shows Adding Lenalidomide Maintenance Therapy to Chemoimmunotherapy Prolongs Progression-Free Survival in High-Risk CLL
The combined use of genetic markers and minimal residual disease assessment (MRD) has made it easier to identify chronic lymphocytic leukemia (CLL) patients likely to have a poor outcome after receiving frontline chemoimmunotherapy. Interim results from the phase III German CLL M1 study presented...
Increased Morbidity and Mortality in HCT Survivors vs Other Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al found that hematopoietic cell transplantation survivors had higher rates of morbidity and mortality compared with a matched population of patients with cancer not undergoing hematopoietic cell transplantation. The study involved...
EORTC-NCI-AACR 2016: ‘Remarkable Antitumor Activity’ in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes provide instructions for making proteins that are part of a family of proteins called receptor...
Advanced Practitioners Convene at Fourth Annual JADPRO Live at APSHO
Launched in 2012 by Harborside Press, publisher of the Journal of the Advanced Practitioner in Oncology (JADPRO) and The ASCO Post, this year’s JADPRO Live at APSHO conference topped previous attendance records with nearly 1,100 attendees. APSHO, the Advanced Practitioner Society in Hematology and...
2016-2017 Oncology Meetings
DECEMBER 58th ASH Annual Meeting & ExpositionDecember 3-6 • San Diego, California For more information: www.hematology.org/Annual-Meeting/ 17th World Conference on Lung CancerDecember 4-7 • Vienna, Austria For more information: www.iaslc.org/events/17th-iaslc-world-conference-lung-cancer 14th...
Sleep Disruption in Cancer Survivors: Yoga Offers a Low-Risk Intervention With High Potential for Benefit
Impaired sleep quality is a concerning problem for many patients with cancer, and pharmacologic treatments come with many negative effects. Several small studies indicate that yoga improves persistent fatigue, sleep disturbance, anxiety, and quality of life, in addition to reducing the need for ...
Making Peace With Cancer
Next to me sounds the buzzing of my Lympha Press machine, which substitutes for the constant visits of the physiotherapist who performs the lymph drainage. This gives me more freedom, and we have more privacy at home. I can use the machine whenever I need it, and my 5-year-old daughter, Christina, ...
Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
In the phase III S-TRAC trial reported at the recent European Society for Medical Oncology meeting and in The New England Journal of Medicine by Alain Ravaud, MD, PhD, of Bordeaux University Hospital, and colleagues, adjuvant sunitinib (Sutent) significantly prolonged disease-free survival vs...
Locally Advanced Esophageal Cancer Outcomes Improved With Neoadjuvant Therapy
In studies presented at the 2016 European Society for Surgical Oncology (ESMO) Congress, two different neoadjuvant treatment approaches improved the outcomes of patients with esophageal cancer. Investigators from the Australasian Gastro-Intestinal Trials Group (AGITG) reported that the addition of...
Numerous ESMO Presentations Focused on Anti–PD-1 Therapy in Lung Cancer and Melanoma
The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti–programmed cell death protein 1 (PD-1) antibodies in non–small cell lung cancer and melanoma, where they have clearly changed the treatment paradigm. Here is a roundup of some of those trials,...
Androgen Receptor Antagonists May Meet ‘Unmet Need’ in Triple-Negative Breast Cancer
Although there are no androgen receptor antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some patients with triple-negative breast cancer, Tiffany A. Traina, MD, told participants at the 18th Annual Lynn Sage Breast Cancer...
Research Highlights From the 2016 Palliative Care in Oncology Symposium
More than 650 attendees gathered in San Francisco on September 9 and 10 for the 2016 Palliative Care in Oncology Symposium, focusing on the theme of “Patient-Centered Care Across the Cancer Continuum.” Research presented during the Symposium demonstrated how integrating palliative care into cancer...
High-Throughput Sequencing of T-Cell Receptors May Transform Diagnosis and Treatment of Cutaneous T-Cell Lymphomas
High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...
Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...
Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?
For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall.1 But the findings of the study were surprising, because neoadjuvant chemotherapy with one-size-fits-all...
